Infliximab, azathioprine, or combination therapy for Crohn's disease.
N Engl J Med. 2010 Sep 9;363(11):1086-8
To the Editor: The Study of Biologic and Immunomodulator Naive Patients in Crohn's Disease (SONIC) (ClinicalTrials.gov number, NCT00094458) reported on by Colombel et al. (April 15 issue)(1) is considered a landmark trial of combination immunosuppressive therapy in Crohn's disease. Several points deserve critical comment. A surprising 41% of the infliximab group did not have mucosal lesions at baseline (Table 2 of the article); this suggests irritable bowel syndrome. Since induction therapy was only administered in the infliximab groups, azathioprine was not given a fair trial - it requires up to 6 months to act. Seven patients have to be treated .Â .Â .
PMID: 20825325 [PubMed - in process]
View the full article